NYX-2925 is being explored primarily for its potential therapeutic applications in neurological and psychiatric disorders. It is currently under investigation as a treatment for chronic pain conditions, particularly neuropathic pain, due to its ability to modulate NMDA receptor activity, which plays a key role in pain signaling pathways. Additionally, it is being studied for its potential benefits in cognitive and mood-related disorders, such as depression and cognitive impairment associated with various neurological conditions. Its mechanism of action involves promoting synaptic plasticity, which could help restore normal brain function in these disorders. Clinical trials are ongoing to evaluate its efficacy and safety in these areas.